Clinical Trial Update: T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) [Phase 1, Phase 2]

View source ↗

Summary

An update on an ongoing Phase 1/2 clinical trial evaluating Estrella Biopharma's EB103 T-cell therapy in adults with relapsed/refractory B-cell non-Hodgkin's ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• EB103

Snippet

Sponsor: Estrella Biopharma, Inc. | Conditions: B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1, Phase 2 | Status: RECRUITING